6th Complement-based Drug Development Summit

With promising clinical data, an increasing number of candidates progressing through the clinic and a rise in diseases where complement drugs are being applied, it's time to accelerate transformative complement-targeted approaches towards approval!

At this exciting time for the field, the 6th Complement-based Drug Development Summit returns to reunite large pharma, innovative biotechs and pioneering academics to explore the full range of next generation complement-targeted technologies, and help you maximize the clinical and commercial success of complement proteins as pan-disease targets!

Join your peers to discuss the intricacies of complement signaling, promising complement targets beyond C3 and C5, translating preclinical research into phase 1a/b investigations, de-risking complement drugs in early trials for both chronic and rare/acute diseases, as well as validating biomarkers of complement activation.

Leverage key learnings and insights with 28+ expert speakers, a content packed two-tracked agenda, a pre-conference workshop on complement in the neuro setting, and new content on the hottest areas of complement R&D.

As the growth potential of emerging complement-targeted therapeutics becomes a reality, this year’s meeting will be your most comprehensive guide for addressing the unique challenges of complement-based drug development, while facilitating meaningful partnerships to power up your market access strategies and pipelines and achieve your 2022/23 milestones.

Prices:
Conference + 1 Workshop (INDUSTRY PRICING) USD 3648.00
Conference Only (INDUSTRY PRICING) USD 2999.00
Conference + 1 Workshop (ACADEMIC PRICING) USD 3148.00
Conference Only (ACADEMIC PRICING) USD 2599.00
Conference + 1 Workshop (STANDARD PRICING) USD 4348.00
Conference Only (STANDARD PRICING) USD 3599.00

Speakers: Ellen Cahir-McFarland Senior Vice President, Research Annexon Biosciences, Madhumita Das Director, Immunology Discovery Apellis Pharmaceuticals, Martin Kolev Associate Director Complement Science Apellis Pharmaceuticals, Axel Vater Founder & Chief Scientific Officer APTARION biotech AG, Emma Persson Scientist, Clinical argenx BV, Cynthia A. Lemere Associate Professor of Neurology Brigham & Women’s Hospital & Harvard Medical School, Gerry Cox Chief Medical Officer CANbridge Pharmaceuticals, Daniel E. Benjamin Chief Executive Officer Cascade Biotechnology Inc., David Heja Senior Scientist eGenesis, Edward F. Patz, Jr CEO & James and Alice Chen Distinguished Professor of Radiology, Pharmacology & Cancer Biology Grid Therapeutics, Duke University School of Medicine, Abhigyan Satyam Assistant Professor Harvard Medical School, Harvard University, Renfeng Guo Chief Science Officer InflaRx N.V., Ruchi Gupta Director Johnson & Johnson, Martin J. Schmidt Chief Scientific Officer Kypha, Michelle Elvington Scientific Director - Complement & Clinical Development Kypha, Bärbel Rohrer Professor Medical University of South Carolina, Stephen Poor Director External Opportunities & Translational Biomarkers Novartis Institutes for Biomedical Research, Stefan Wawersik Vice President of Research Q32 Bio Inc., Ulrich Thienel Chief Executive Officer ReAlta Life Sciences, Michael Storek Head of Complement Cluster Sanofi, Michael Schwenkert Chief Technology Officer Svar, Jeffry B. Lawrence Interim Vice President, Clinical Development Solid Biosciences, Maciej Markiewski Professor Texas Tech University Health Sciences Center, Douangsone Vadysirisack Translational Biology Lead UCB, Petra Duda Head of Development – Zilucoplan UCB, Dorothy Schafer Associate Professor of Neurobiology UMass Chan Medical School, Nirmal K. Banda Professor University of Colorado Anschutz Medical Campus, Karthik Viswanathan Executive Director, Research Visterra, Inc., Keith Wilcoxen Senior Vice President, Global Research Zenas BioPharma

Others Details

Brochure https://go.evvnt.com/1152295-3?pid=6581